ENHERTU: One Year On – Reflecting on Success, Optimising Strategies & Revisiting the ADC ‘Poster Child’ Case
Time: 8:30 am
day: Conference Day One
Details:
- Evaluating the remarkable progress of ENHERTU following its unprecedented triumph in HER-2 negative breast cancer and looking into broadening out applications in a pan-tumour study
- Analysing the distinctive characteristics of ENHERTU that contributed to its triumph, including the low potency payload, linker cleavability, and bystander effect – identifying which aspects can pave the way for future ADC advancements
- Pondering the significance of ENHERTU’s success in shaping the future of ADC design and the potential for repurposing approved ADCs in novel therapeutic indications
